cagrilintide dosage PDF] Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial dosing for cagrilintide Cagrilintide 10mg

This is the second head-to-head study after Eli Lilly registered its intent to carry out a Phase 3b clinical trial in April 2023 that will see the companys tirzepatide (Mounjaro) compared with Novo Nordisks semaglutide (Wegovy) 2.4mg in 700 adult participants who have obesity or overweight with weight related comorbidities without Type 2 diabetes

In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population

Share your story below

BPC-157 also modulates the nitric oxide system, activates the FAK-paxillin pathway for fibroblast migration, and promotes collagen deposition at injury sites